Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Amortizatization of Intangibles: 2022-2025

Historic Amortizatization of Intangibles for InMed Pharmaceuticals (INM) over the last 4 years, with Jun 2025 value amounting to $321,885.

  • InMed Pharmaceuticals' Amortizatization of Intangibles rose 14.47% to $103,478 in Q3 2025 from the same period last year, while for Sep 2025 it was $334,962, marking a year-over-year decrease of 10.96%. This contributed to the annual value of $321,885 for FY2025, which is 16.38% down from last year.
  • According to the latest figures from FY2025, InMed Pharmaceuticals' Amortizatization of Intangibles is $321,885, which was down 16.38% from $384,918 recorded in FY2024.
  • In the past 5 years, InMed Pharmaceuticals' Amortizatization of Intangibles ranged from a high of $393,748 in FY2023 and a low of $321,885 during FY2025.
  • Moreover, its 3-year median value for Amortizatization of Intangibles was $384,918 (2024), whereas its average is $366,850.
  • As far as peak fluctuations go, InMed Pharmaceuticals' Amortizatization of Intangibles climbed by 20.73% in 2023, and later declined by 16.38% in 2025.
  • InMed Pharmaceuticals' Amortizatization of Intangibles (Yearly) stood at $326,133 in 2022, then climbed by 20.73% to $393,748 in 2023, then fell by 2.24% to $384,918 in 2024, then fell by 16.38% to $321,885 in 2025.